Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 40Recurrence 9Neoplasms, Plasma Cell 7Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, B-Cell 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Leukemia, Myeloid, Acute 1Intraocular Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Epstein-Barr Virus Infections 1Disease Progression 1Disease 1Central Nervous System Neoplasms 1Amyloidosis 1

Interventions

miridesap 3Dexamethasone 2Calcium Dobesilate 2venetoclax 1pomalidomide 1pegfilgrastim 1Technetium Tc 99m Pyrophosphate 1Technetium 1Surveys and Questionnaires 1Melphalan 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Amyloidosis × pomalidomide × Clear all
NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Plasma cell

Amyloidosis, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡